---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000019"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:22:08.202728+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akebia extends separation dates for COO Dahan to June 28 and CLO Hadas to June 14

## Summary
- COO Michel Dahan's separation extended from March 22 to June 28, 2024.
- SVP/Chief Legal Officer Nicole Hadas separation extended from March 29 to June 14, 2024.
- Both amendments signed on February 8, 2024; earlier retention agreements dated May 5, 2022.
- Separations may further extend to Sept 22, 2024 upon certain specified events.

## SEC filing metadata
- accession: 0001517022-24-000019
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/0001517022-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/akba-20240208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000019
- JSON: https://secwatch.observer/filing/0001517022-24-000019.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000019.txt

## Key facts
- Executive change
  Nicole R. Hadas departed as Senior Vice President, Chief Legal Officer and Secretary at Akebia Therapeutics, Inc..
  - Action: separation extended
  - Role: Senior Vice President, Chief Legal Officer and Secretary
  source text: On February 8, 2024, the Company and Ms. Hadas agreed to further extend the effective date of her separation to June 14, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/0001517022-24-000019-index.htm
- Executive change
  Michel Dahan departed as Chief Operating Officer at Akebia Therapeutics, Inc..
  - Action: separation extended
  - Role: Chief Operating Officer
  source text: On February 8, 2024, the Company and Mr. Dahan agreed to further extend the effective date of his separation to June 28, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000019/0001517022-24-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.